Lea Eslava-Kim, PharmD

Drug Information Specialist https://www.neurologyadvisor.com

Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.

All articles by Lea Eslava-Kim, PharmD

news

FDA Reviewing Potential Treatment for Levodopa-Induced Dyskinesia

The FDA has accepted the NDA for ADS-5102 for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

Lea Eslava-Kim, PharmD

January 9, 2017

news

FDA Fast Tracks Potential Neuropathy Treatment

The designation has been granted to potentially treat neuropathic pain associated with diabetic peripheral neuropathy.

Lea Eslava-Kim, PharmD

September 27, 2016

news

OV101 Wins Orphan Drug Status for Rare Neurological Disorder

The treatment is currently being investigated in a Phase 2 trial in adults with Angelman syndrome

Lea Eslava-Kim, PharmD

September 13, 2016

news

FDA Accepts NDA for Controlled Opioid Agonist

The FDA has accepted an NDA for Arymo ER (morphine sulfate; Egalet) extended-release tablets.

Lea Eslava-Kim, PharmD

March 3, 2016

news

NDA Submitted for Duchenne Muscular Dystrophy Drug

Translarna (ataluren) is for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).

Lea Eslava-Kim, PharmD

January 8, 2016

news

Novel Huntington’s Treatment Wins Orphan Drug Status

The FDA has granted Orphan Drug designation to IONIS-HTT (Ionis) for the treatment of Huntington’s disease.

Lea Eslava-Kim, PharmD

January 13, 2016